Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Myriad Genetics (MYGN) Other Operating Expenses (2016 - 2025)

Myriad Genetics (MYGN) has disclosed Other Operating Expenses for 17 consecutive years, with $71.4 million as the latest value for Q4 2025.

  • On a quarterly basis, Other Operating Expenses fell 23.88% to $71.4 million in Q4 2025 year-over-year; TTM through Dec 2025 was $600.2 million, a 140.37% increase, with the full-year FY2025 number at $600.2 million, up 87.8% from a year prior.
  • Other Operating Expenses was $71.4 million for Q4 2025 at Myriad Genetics, up from $71.0 million in the prior quarter.
  • In the past five years, Other Operating Expenses ranged from a high of $388.6 million in Q2 2025 to a low of $2.2 million in Q3 2024.
  • A 5-year average of $89.8 million and a median of $70.2 million in 2024 define the central range for Other Operating Expenses.
  • Peak YoY movement for Other Operating Expenses: crashed 97.61% in 2024, then surged 3127.27% in 2025.
  • Myriad Genetics' Other Operating Expenses stood at $106.1 million in 2021, then rose by 17.72% to $124.9 million in 2022, then fell by 7.45% to $115.6 million in 2023, then fell by 18.86% to $93.8 million in 2024, then dropped by 23.88% to $71.4 million in 2025.
  • Per Business Quant, the three most recent readings for MYGN's Other Operating Expenses are $71.4 million (Q4 2025), $71.0 million (Q3 2025), and $388.6 million (Q2 2025).